<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774449</url>
  </required_header>
  <id_info>
    <org_study_id>5108</org_study_id>
    <nct_id>NCT00774449</nct_id>
  </id_info>
  <brief_title>Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation</brief_title>
  <official_title>Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic organ dysfunction after lung transplantation (BOS) is the most common cause of death&#xD;
      in long-term survivors after lung transplantation and refractory to most interventions. Early&#xD;
      markers will be established in this project study to overcome the problem of disease&#xD;
      recognition when impairment of graft function is already taken place. Long-term longitudinal&#xD;
      monitoring in stable recipients of innovative markers of airway inflammation and ventilation&#xD;
      and new imaging techniques will define different entities of chronic organ dysfunction after&#xD;
      LTx. A database and specimen service unit for further projects will be created.&#xD;
&#xD;
      Hypothesis: This project will reveal new markers and imaging tools in recipients who develop&#xD;
      BOS after lung transplantation. These tools will allow earlier diagnosis and more accurate&#xD;
      monitoring of the disease process. Different patterns of the disease will be characterized.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic organ dysfunction of the lung allograft is the most common cause of death in lung&#xD;
      transplant recipients after the first postoperative year and is a major cause of morbidity in&#xD;
      the long-term care. It affects every second recipient surviving 5 years after transplantation&#xD;
      (Boehler, Estenne 2003). Obliterative bronchiolitis (OB) is the histo-pathological process&#xD;
      underlying chronic organ dysfunction after LTx. Bronchiolitis obliterans syndrome (BOS) is&#xD;
      the clinical definition of chronic organ dysfunction following lung transplantation (LTx) and&#xD;
      refers to a progressive obstructive ventilatory disorder. Staging is performed according to&#xD;
      baseline values of forced expiratory volume after LTx (Estenne et al. 2001).&#xD;
&#xD;
      Excessive immunosuppression may be deleterious by increasing the risk of infection, thereby&#xD;
      triggering innate and adaptive immunity. BOS is progressive in most of the cases with&#xD;
      stabilisation in some. Different clinical entities are found according to time of onset,&#xD;
      speed of decline in graft function (Jackson et al. 2002), ventilatory patterns, findings on&#xD;
      imaging studies (Pakhale et al 2005, Choi et al 2003) and response to macrolides (Gerhardt et&#xD;
      al. 2003). Exhaled biomarkers are promising markers of disease activity in pats with BOS (an&#xD;
      Muylem 2007, Brugiere et al 2005) Alloimmune-independent and -dependent mechanisms produce&#xD;
      injuries and inflammation of epithelial cells and subepithelial structures, leading to&#xD;
      aberrant tissue repair (Nicod et al 2006). The triggering of innate immunity by various&#xD;
      infections (especially respiratory viruses, Khalifah et al 2004) or chemical injuries (e.g.&#xD;
      gastroesophageal reflux or aspiration, Palmer et al. 2000), may lead to the release of danger&#xD;
      signals that are able to activate dendritic cells, a crucial link with adaptive immunity.&#xD;
      Inflammation can also increase the expression and display of major histocompatibility&#xD;
      alloantigens and thus favor the initiation of rejection episodes. The injuries evoke a&#xD;
      proinflammatory response and cellular infiltration that leads to excessive fibroproliferation&#xD;
      and results in matrix deposition and vascular remodelling. These phenomena may be limited in&#xD;
      time and location or may be protracted. Reducing the risk of alloimmune-independent factors&#xD;
      may be as important as treating acute episodes of lung rejection.&#xD;
&#xD;
      Newpotential therapeutic targets are emerging from the research performed on leukotriene&#xD;
      receptors, chemokine receptors, and growth factors. Neutralizing these molecules may reduce&#xD;
      the initial mononuclear and polynuclear infiltrates or the subsequent fibroproliferative&#xD;
      process and the neovascular changes, feeding this process. (Nicod 2006). Macrolides are&#xD;
      promising new agents which partially reverse loss of graft function in a subgroup of&#xD;
      patients, which may change definition of BOS in the near future (Gerhardt et al 2003).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchiolitis obliterans Syndrom (BOS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">261</enrollment>
  <condition>Lung Transplantation</condition>
  <condition>Bronchiolitis Obliterans Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bronchoalveolar lavage, transbronchial biopsies, blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at&#xD;
        Hannover Medical School 6 months prior to inclusion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx)&#xD;
             at Hannover Medical School 6 months prior to inclusion&#xD;
&#xD;
          -  Ages: 18 to 68 Years&#xD;
&#xD;
          -  Gender: both&#xD;
&#xD;
          -  Stable graft function (FEV1 &gt;90% baseline)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe airway complications after surgery necessitating repeated intervention during&#xD;
             the last 3 months&#xD;
&#xD;
          -  Need for supplemental oxygen at time of inclusion&#xD;
&#xD;
          -  Single lung (SLTx) and living lobar recipients&#xD;
&#xD;
          -  Established diagnosis of BOS at time of inclusion&#xD;
&#xD;
          -  Inability to undergo bodyphlethysmography e.g. due to persistent infection with&#xD;
             multi-drug resistant bacteria (MRSA, VRE, Burkholderia Cepacia, Pandorea)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Gottlieb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Gottlieb, MD</last_name>
    <phone>+49-511-532</phone>
    <phone_ext>3560</phone_ext>
    <email>gottlieb.jens@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Gottlieb, MD</last_name>
      <phone>+49-511-532</phone>
      <phone_ext>3560</phone_ext>
      <email>gottlieb.jens@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Jens Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Jens Gottlieb</name_title>
    <organization>Hannover Medical School, Department of Respiratory Medicine</organization>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>bronchiolitis obliterans syndrome</keyword>
  <keyword>broncholaveolar lavage</keyword>
  <keyword>high-resolution computertomography</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

